2025-12-25 - Analysis Report
Here's a comprehensive analysis of TransMedics Group Inc. (TMDX) based on the provided data.

**1. Return Rate Comparison with S&P 500 (VOO)**

*   **Company Overview:** TransMedics Group Inc. (TMDX) is a medical technology company focused on developing and delivering innovative organ care system (OCS) technology for end-stage organ failure patients.
*   **TMDX Cumulative Return:** 214.22%
*   **VOO Cumulative Return:** 76.12%
*   **Divergence:**
    *   Current: 138.1
    *   Relative Divergence: 66.1% (This means the current divergence is positioned at the 66.1th percentile within its historical range.)

**Analysis of Alpha, Beta, CAGR, and MDD:**

|            Year |    CAGR |   MDD |   Alpha |   Beta |   Cap(B) |
|-----------------:|--------:|------:|--------:|-------:|---------:|
|        2019-2021 |  -18.0% | 83.5% |  -61.0% |   -0.0 |      0.7 |
|        2020-2022 |   94.0% | 83.5% |   95.0% |    0.0 |      2.1 |
|        2021-2023 |   65.0% | 80.5% |   64.0% |    0.1 |      2.7 |
|        2022-2024 |  130.0% | 85.5% |  109.0% |    0.1 |      2.1 |
|        2023-2025 |  135.0% | 85.5% |   70.0% |    0.3 |      4.3 |

*   **CAGR (Compound Annual Growth Rate):** CAGR shows very strong growth in recent periods (2020-2025), highlighting significant performance. Note the negative CAGR during 2019-2021, suggesting early volatility.
*   **MDD (Maximum Drawdown):**  High MDD across all periods (above 80%) indicates significant volatility and risk in TMDX stock.  Investors should be prepared for substantial price swings.
*   **Alpha:** Alpha has been largely positive, suggesting that TMDX has outperformed its benchmark (S&P 500) on a risk-adjusted basis, except for the period 2019-2021.
*   **Beta:** Beta is generally low (around 0), indicating that TMDX's price movements are not strongly correlated with the S&P 500.
*   **Cap(B):** Market Cap generally trending upwards

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 127.67
*   **Last Market Data:** Price: 126.99, Previous Close: 128.2, Change: -0.94
*   **5-day SMA:** 123.77
*   **20-day SMA:** 134.25
*   **60-day SMA:** 124.88

The current price is below the 20-day SMA but above the 60-day SMA. The 5-day SMA is also below the current price. This suggests a potential short-term downward trend, but the price is still holding above the longer-term (60-day) average. The last market data shows a small decline, which can reflect the price volatility.

**3. RSI, PPO, Divergence, and Expected Return Analysis**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 25.77 (Oversold)
*   **PPO:** -1.42
*   **Hybrid Signal:** Buy 100% of cash (7 shares)
*   **Recent Divergence Change:** 0.6 (+) (Indicates Short-Term Increase)
*   **Expected Return:** 47.6% (Long-term)

**Analysis:**

*   The **MRI of 0.8** suggests a medium level of investment risk.
*   The **RSI of 25.77** indicates that the stock is currently oversold, which could suggest a potential buying opportunity as the stock may be undervalued in the short term.
*   A **negative PPO (-1.42)** typically suggests that short-term momentum is weaker than long-term momentum.
*   The **Hybrid Signal** recommends buying 100% of cash, suggesting a favorable outlook based on the model's criteria.
*   The **recent increase in relative divergence (0.6)** indicates short-term upward momentum.
*   The **expected return of 47.6%** over the long term is significant and suggests potential for substantial gains.

**4. Recent News & Significant Events**

*   **[2025-12-24] Seeking Alpha: TransMedics Stock: I Estimate An Upside Of Nearly 150% By The End Of 2028:** Positive news indicating a strong upside potential in the long term.
*   **[2025-10-30] Yahoo Finance: TMDX Stock Falls Despite Q3 Earnings Beat Estimates:** Although the company beat earnings estimates, the stock fell, possibly due to market expectations or other factors.
*   **[2025-12-20] MarketBeat: Zevenbergen Capital Investments LLC Increases Stock Position in TransMedics Group, Inc.:** A major institutional investor increasing their stake is generally a positive sign, indicating confidence in the company's future.
*   **[2025-12-23] Stock Traders Daily: Behavioral Patterns of TMDX and Institutional Flows:** Monitoring institutional flows and behavioral patterns can provide insights into potential market movements.
*   **[2025-12-22] Investing.com: TransMedics stock could see upside from heart trial, Piper Sandler says:** News about positive trial outcomes can positively impact the stock price.
*   **[2025-12-08] Quiver Quantitative: TransMedics Group Stock (TMDX) Opinions on Recent Insider Sales:** Insider sales can be a red flag, but further investigation is needed to understand the reasons behind the sales.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.67)
*   **Target Price:** Average: 144.73, High: 170.00, Low: 114.00

**Analysis:**
The analyst consensus is "Buy," and the target prices indicate a potential upside from the current price. The analyst's high target price ($170.00) presents the highest potential upside.

**5. Comprehensive Analysis**

TransMedics (TMDX) is a high-growth, high-volatility stock. The company has significantly outperformed the S&P 500 in recent years, as evidenced by the superior cumulative returns and positive alpha. Recent news is mixed, including a fall despite earnings beats, which can reflect short-term market dynamics. However, the news also includes positive long-term forecasts, increased institutional investment, and positive commentary regarding trial results and analyst opinions.

*   **Strengths:**
    *   High growth potential (high CAGR, high expected return)
    *   Outperformance relative to the market (positive alpha)
    *   Favorable analyst consensus (Buy rating with potential upside)
    *   Recent institutional investment increases
    *   Promising trial results for heart trials
*   **Weaknesses:**
    *   High volatility (high MDD)
    *   Recent stock price fluctuations and mixed market reactions
    *   Insider sales can be concerning

**Overall Recommendation:**

Based on the analysis, TransMedics presents a compelling investment opportunity for investors with a high-risk tolerance and a long-term investment horizon. The company's strong growth prospects, positive analyst ratings, and recent institutional investment suggest potential for significant returns. However, investors should be aware of the high volatility and potential for significant price swings.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.